IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
25.90
-0.27 (-1.03%)
Nov 20, 2026, 12:24 PM EST - Market open
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $10.24M in the quarter ending September 30, 2026, a decrease of -95.07%. This brings the company's total for the last twelve months to $36.54M, down -82.99% year-over-year. In the year 2025, IDEAYA Biosciences had annual revenue of $218.71M with 3,024.43% growth. That makes IDEAYA Biosciences the 30,166th largest company in the world by revenue and 3,980th in the United States.
Revenue (ttm)
$36.54M
Revenue Growth
-82.99%
P/S Ratio
69.90
Revenue / Employee
$251,972
Employees
145
Market Cap
2.50B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 218.71M | 211.71M | 3,024.43% |
| Dec 31, 2024 | 7.00M | -16.39M | -70.07% |
| Dec 31, 2023 | 23.39M | -27.55M | -54.08% |
| Dec 31, 2022 | 50.93M | 22.99M | 82.28% |
| Dec 31, 2021 | 27.94M | 8.40M | 43.01% |
| Dec 31, 2020 | 19.54M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 890.79M |
| ADMA Biologics | 519.15M |
| Zai Lab | 441.73M |
| Xencor | 200.49M |
| Arcus Biosciences | 100.00M |
| NewAmsterdam Pharma Company | 25.94M |
| Celldex Therapeutics | 158.00K |
IDYA News
- 4 hours ago - Ideaya Biosciences price target lowered to $55 from $62 at JPMorgan - TheFly
- 3 days ago - Ideaya Biosciences falls -11.8% - TheFly
- 3 days ago - IDEAYA Biosciences Transcript: Jefferies Global Healthcare Conference - Transcripts
- 3 days ago - Ideaya Biosciences reports on FDA Type C meeting on Phase 2/3 trial for IDE849 - TheFly
- 3 days ago - IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas - PRNewsWire
- 3 days ago - IDEAYA Biosciences Transcript: R&D Day 2026 - Transcripts
- 3 days ago - IDEAYA Biosciences Slides: FY 2026 - Filings
- 4 days ago - IDEAYA Biosciences Transcript: UBS Global Biopharma Conference 2026 - Transcripts